BIOA earnings analysis
What we found in BIOA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BioAge Labs reported strong financial performance in Q1 2026, with significant revenue growth driven by its collaboration with Novartis. The company continues to face challenges, including heavy operating losses and compliance with regulatory requirements as it advances clinical trials for BGE-102. Management remains optimistic about future clinical developments and maintains a strong liquidity position with ample cash reserves.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Revenue Increase
- Reported revenue reached $2.772 million in Q1 2026, up 91.1% from $1.451 million in Q1 2025.
- Improvement in EPS
- Net loss per share improved to -$0.72 in Q1 2026 from -$0.73 in the prior quarter.
- Strong Cash Position
- As of March 31, 2026, the company reported $384.9 million in cash, cash equivalents, and marketable securities.
- R&D Investment Growth
- Research and development expenses increased to $20.410 million in Q1 2026, reflecting ongoing clinical development.
- Continued Clinical Development
- Management expects to initiate Phase 2 trials for BGE-102 in mid-2026, with results anticipated by year-end.
- Successful Completion of Phase 1 Trials
- BGE-102 showed promising results in Phase 1 trials, leading to significant optimism for upcoming phases.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Operating Losses Persist
- Net losses widened to $22.253 million in Q1 2026 from $12.928 million a year earlier.
- Dependence on Collaboration Success
- Future revenues heavily rely on successful outcomes from the ongoing collaboration with Novartis.
- Potential Regulatory Challenges
- Future developments face risks related to government regulations and FDA approval processes that could delay product launch.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.72
- Segment
- Collaboration Revenue: $2.772 million
- Segment
- Operating Losses: $25,375 million
What they said about what is next.
Management anticipates continued revenue growth from collaboration efforts.
The filing reads better than the one before it.
What came before.
- 10-K · March 24, 2026
- BioAge positions itself as a platform-driven, clinical-stage biotech focused on aging biology with a lead program BGE-102 (oral, brain-penetrant NLRP3 inhibitor) and APJ programs for obesity. The 10‑K highlights strong…
- 10-Q · August 6, 2025
- BioAge reported $2.412M of collaboration revenue in Q2 2025 and a GAAP net loss of $21.563M (EPS -$0.60). R&D and G&A spending rose materially (R&D $19.844M, G&A $7.339M), increasing operating loss to $24.771M vs…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BIOA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever